Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway

Cancer Cell

Volumn 6, Issue 1, 2004, Pages 33-43

  Kung, Andrew L ^a,b   Zabludoff, Sonya D ^c,f   France, Dennis S ^c   Freedman, Steven J ^a,d,g   Tanner, Elizabeth A ^a   Vieira, Annelisa ^a   Cornell Kennon, Susan ^c   Lee, Jennifer ^c   Wang, Beqing ^c   Wang, Jamin ^c   Memmert, Klaus ^e   Naegeli, Hans Ulrich ^e   Petersen, Frank ^e   Eck, Michael J ^a   Bair, Kenneth W ^c,e   Wood, Alexander W ^c   Livingston, David M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c NOVARTIS PHARMA K K   (Japan)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f ASTRAZENECA   (United Kingdom)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE ACETYLTRANSFERASE PCAF; HYPOXIA INDUCIBLE FACTOR 1;

ARTICLE; CONTROLLED STUDY; FEASIBILITY STUDY; HUMAN; HUMAN CELL; HYPOXIA; MOLECULE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR GROWTH;

EID: 3142622930     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.06.009     Document Type: Article

References (53)

1. Arany Z., Huang L.E., Eckner R., Bhattacharya S., Jiang C., Goldberg M.A., Bunn H.F., Livingston D.M. An essential role for p300/CBP in the cellular response to hypoxia. Proc. Natl. Acad. Sci. USA. 93:1996;12969-12973
2. Balasubramanyam K., Swaminathan V., Ranganathan A., Kundu T.K. Small molecule modulators of histone acetyltransferase p300. J. Biol. Chem. 278:2003;19134-19140
3. Berg T., Cohen S.B., Desharnais J., Sonderegger C., Maslyar D.J., Goldberg J., Boger D.L., Vogt P.K. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc. Natl. Acad. Sci. USA. 99:2002;3830-3835
4. Bhattacharya S., Eckner R., Grossman S., Oldread E., Arany Z., D'Andrea A., Livingston D.M. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-α Nature. 383:1996;344-347
5. Bhattacharya S., Michels C.L., Leung M.K., Arany Z.P., Kung A.L., Livingston D.M. Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. Genes Dev. 13:1999;64-75
6. Brewer D., Duncan J.M., Jerram W.A., Leach C.K., Safe S., Taylor A., Vining L.C., Archibald R.M., Stevenson R.G., Mirocha C.J., Christensen C.M. Ovine ill-thrift in Nova Scotia. 5. The production and toxicology of chetomin, a metabolite of chaetomium spp. Can. J. Microbiol. 18:1972;1129-1137
7. Brown J.M. Tumor microenvironment and the response to anticancer therapy. Cancer Biol. Ther. 1:2002;453-458
8. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394:1998;485-490
9. Carrero P., Okamoto K., Coumailleau P., O'Brien S., Tanaka H., Poellinger L. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1α Mol. Cell. Biol. 20:2000;402-415
10. Cochran A.G. Antagonists of protein-protein interactions. Chem. Biol. 7:2000;R85-R94
11. Damert A., Machein M., Breier G., Fujita M.Q., Hanahan D., Risau W., Plate K.H. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Res. 57:1997;3860-3864
12. Darnell J.E. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer. 2:2002;740-749
13. Ema M., Hirota K., Mimura J., Abe H., Yodoi J., Sogawa K., Poellinger L., Fujii-Kuriyama Y. Molecular mechanisms of transcription activation by HLF and HIF1α in response to hypoxia. their stabilization and redox signal-induced interaction with CBP/p300 EMBO J. 18:1999;1905-1914
14. Foster B.A., Coffey H.A., Morin M.J., Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science. 286:1999;2507-2510
15. Freedman S.J., Sun Z.Y., Poy F., Kung A.L., Livingston D.M., Wagner G., Eck M.J. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1α Proc. Natl. Acad. Sci. USA. 99:2002;5367-5372
16. Freedman S.J., Sun Z.Y., Kung A.L., France D.S., Wagner G., Eck M.J. Structural basis for negative regulation of hypoxia-inducible factor-1α by CITED2. Nat. Struct. Biol. 10:2003;504-512
17. Fujimoto H., Sumino M., Okuyama E., Ishibashi M. Immunomodulatory constituents from an Ascomycete, Chaetomium seminudum. J. Nat. Prod. 67:2004;98-102
18. Fukumura D., Xavier R., Sugiura T., Chen Y., Park E.C., Lu N., Selig M., Nielsen G., Taksir T., Jain R.K., Seed B. Tumor induction of VEGF promoter activity in stromal cells. Cell. 94:1998;715-725
19. Gu J., Milligan J., Huang L.E. Molecular mechanism of hypoxia-inducible factor 1α-p300 interaction. A leucine-rich interface regulated by a single cysteine. J. Biol. Chem. 276:2001;3550-3554
20. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer. 2:2002;38-47
21. Hockel M., Vaupel P. Biological consequences of tumor hypoxia. Semin. Oncol. 28:2001;36-41
22. Hopfl G., Wenger R.H., Ziegler U., Stallmach T., Gardelle O., Achermann R., Wergin M., Kaser-Hotz B., Saunders H.M., Williams K.J., et al. Rescue of hypoxia-inducible factor-1α-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor. Cancer Res. 62:2002;2962-2970
23. Huang L.E., Bunn H.F. Hypoxia-inducible factor and its biomedical relevance. J. Biol. Chem. 278:2003;19575-19578
24. Huang L.E., Gu J., Schau M., Bunn H.F. Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA. 95:1998;7987-7992
25. Hur E., Kim H.H., Choi S.M., Kim J.H., Yim S., Kwon H.J., Choi Y., Kim D.K., Lee M.O., Park H. Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1α/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol. Mol. Pharmacol. 62:2002;975-982
26. Isaacs J.S., Jung Y.J., Mimnaugh E.G., Martinez A., Cuttitta F., Neckers L.M. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway. J. Biol. Chem. 277:2002;29936-29944
27. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J.M., Lane W.S., Kaelin W.G. Jr. HIFα targeted for VHL-mediated destruction by proline hydroxylation. implications for O2 sensing Science. 292:2001;464-468
28. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., Kriegsheim A., Hebestreit H.F., Mukherji M., Schofield C.J., et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 292:2001;468-472
29. Kallio P.J., Wilson W.J., O'Brien S., Makino Y., Poellinger L. Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J. Biol. Chem. 274:1999;6519-6525
30. Kondo K., Klco J., Nakamura E., Lechpammer M., Kaelin W.G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 1:2002;237-246
31. Kung A.L., Wang S., Klco J.M., Kaelin W.G., Livingston D.M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med. 6:2000;1335-1340
32. Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L., Bruick R.K. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16:2002;1466-1471
33. Lau O.D., Kundu T.K., Soccio R.E., Ait-Si-Ali S., Khalil E.M., Vassilev A., Wolffe A.P., Nakatani Y., Roeder R.G., Cole P.A. HATs off. selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF Mol. Cell. 5:2000;589-595
34. Lepourcelet M., Chen Y.N., France D.S., Wang H., Crews P., Petersen F., Bruseo C., Wood A.W., Shivdasani R.A. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell. 5:2004;91-102
35. Mabjeesh N.J., Post D.E., Willard M.T., Kaur B., Van Meir E.G., Simons J.W., Zhong H. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res. 62:2002;2478-2482
36. Mabjeesh N.J., Escuin D., LaVallee T.M., Pribluda V.S., Swartz G.M., Johnson M.S., Willard M.T., Zhong H., Simons J.W., Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell. 3:2003;363-375
37. Masson N., Willam C., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J. 20:2001;5197-5206
38. McInnes A.G., Taylor A., Walter J.A. The structure of chetomin. J. Am. Chem. Soc. 98:1976;6741
39. Mie Lee Y., Kim S.H., Kim H.S., Jin Son M., Nakajima H., Jeong Kwon H., Kim K.W. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1α activity. Biochem. Biophys. Res. Commun. 300:2003;241-246
40. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., Kinzler K.W. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science. 275:1997;1787-1790
41. Pugh C.W., Ratcliffe P.J. Regulation of angiogenesis by hypoxia. role of the HIF system Nat. Med. 9:2003;677-684
42. Rapisarda A., Uranchimeg B., Scudiero D.A., Selby M., Sausville E.A., Shoemaker R.H., Melillo G. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62:2002;4316-4324
43. Ray P., Pimenta H., Paulmurugan R., Berger F., Phelps M.E., Iyer M., Gambhir S.S. Noninvasive quantitative imaging of protein-protein interactions in living subjects. Proc. Natl. Acad. Sci. USA. 99:2002;3105-3110
44. Ryan H.E., Lo J., Johnson R.S. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J. 17:1998;3005-3015
45. Ryan H.E., Poloni M., McNulty W., Elson D., Gassmann M., Arbeit J.M., Johnson R.S. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res. 60:2000;4010-4015
46. Sekita S., Yoshihira K., Natori S., Udagawa S., Muroi T., Sugiyama Y., Kurata H., Umeda M. Mycotoxin production by Chaetomium spp., and related fungi. Can. J. Microbiol. 27:1981;766-772
47. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol. 64:2002;993-998
48. Sowter H.M., Raval R.R., Moore J.W., Ratcliffe P.J., Harris A.L. Predominant role of hypoxia-inducible transcription factor (Hif)-1α versus Hif-2α in regulation of the transcriptional response to hypoxia. Cancer Res. 63:2003;6130-6134
49. Vaupel P., Thews O., Kelleher D.K., Hoeckel M. Current status of knowledge and critical issues in tumor oxygenation. Results from. 25(years research in tumor pathophysiology. Adv. Exp. Med. Biol. 454):1998;591-602
50. von Pawel J., von Roemeling R., Gatzemeier U., Boyer M., Elisson L.O., Clark P., Talbot D., Rey A., Butler T.W., Hirsh V., et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer. A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors J. Clin. Oncol. 18:2000;1351-1359
51. Yamakawa M., Liu L.X., Date T., Belanger A.J., Vincent K.A., Akita G.Y., Kuriyama T., Cheng S.H., Gregory R.J., Jiang C. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ. Res. 93:2003;664-673
52. Zhang J.H., Chung T.D., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:1999;67-73
53. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., Simons J.W. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 59:1999;5830-5835